相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inclisiran: First Approval
Yvette N. Lamb
DRUGS (2021)
CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
Harry E. Walker et al.
METABOLITES (2021)
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Amir Abbas Momtazi-Borojeni et al.
VACCINES (2021)
Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems
Laurits Fredsgaard et al.
VACCINES (2021)
A Single-Dose, Implant-Based, Trivalent Virus-like Particle Vaccine against Cholesterol Checkpoint Proteins
Oscar A. Ortega-Rivera et al.
ADVANCED THERAPEUTICS (2021)
Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines
Kara-Lee Aves et al.
VIRUSES-BASEL (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Hyun-Duk Jang et al.
EUROPEAN HEART JOURNAL (2020)
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Amir Abbas Momtazi-Borojeni et al.
ATHEROSCLEROSIS (2019)
Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
Amelia Escolano et al.
NATURE (2019)
Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination
Anna-Karin E. Palm et al.
FRONTIERS IN IMMUNOLOGY (2019)
被撤回的出版物: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis (Retracted article. See vol. 21, 2023)
Amir Abbas Momtazi-Borojeni et al.
BMC MEDICINE (2019)
PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
NATURE REVIEWS CARDIOLOGY (2019)
Inflammatory and Cholesterol Risk in the FOURIER Trial
Erin A. Bohula et al.
CIRCULATION (2018)
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation
Nabil G. Seidah et al.
CURRENT OPINION IN LIPIDOLOGY (2018)
Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
Ryo Kawakami et al.
PLOS ONE (2018)
New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue
Karl D. Brune et al.
FRONTIERS IN IMMUNOLOGY (2018)
Virus-like particle display of HER2 induces potent anti-cancer responses
Arianna Palladini et al.
ONCOIMMUNOLOGY (2018)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Carl E. Orringer et al.
Journal of Clinical Lipidology (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice
David Sinning et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
A Therapeutic Peptide Vaccine Against PCSK9
Yajie Pan et al.
SCIENTIFIC REPORTS (2017)
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report
Xiao Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Moving towards a new class of vaccines for non-infectious chronic diseases
Bryce Chackerian et al.
EXPERT REVIEW OF VACCINES (2016)
Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes
Claudia Cavelti-Weder et al.
MOLECULAR THERAPY (2016)
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Bacterial superglue enables easy development of efficient virus-like particle based vaccines
Susan Thrane et al.
JOURNAL OF NANOBIOTECHNOLOGY (2016)
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Karl D. Brune et al.
SCIENTIFIC REPORTS (2016)
A cholesterol-lowering VLP vaccine that targets PCSK9
Erin Crossey et al.
VACCINE (2015)
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease
Martin R. Farlow et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2013)
Active immunotherapy for chronic diseases
Martin F. Bachmann et al.
VACCINE (2013)
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Liwen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
Bijan Zakeri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Martin F. Bachmann et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure:: a double-blind, randomised, placebo-controlled phase IIa study
Alain C. Tissot et al.
LANCET (2008)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Opinion - Therapeutic vaccination for chronic diseases: a new class of drugs in sight
MF Bachmann et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
